CheckMate-214, 2017 trial summary

A randomised clinical trial investigating the effect of nivolumab + ipilimumab versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma

        Z

NCT02231749    



Studied treatment nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks
Control treatment sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment



Patients intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma
Group sizes-9 / -9



Blindness open-label Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint ORR, PFS, OS Design Parallel groups

phase 3



EndpointX1N1X0N0TE95% CI PFS - -9 - -9 0,82[0,64; 1,05] ORR - -9 - -9 no data OS - -9 - -9 0,68[0,49; 0,95]0,22,01,0



Registering number NCT02231749 (see trial on clinicaltrials.gov)
Code Name